Posted by Michael Wonder on 12 May 2021
Alume Biosciences granted FDA fast track designation of ALM-488 for surgical nerve visualisation
12 May 2021 - Fast track designation highlights the urgent need for improved intra-operative nerve identification.
Alume Biosciences today announced that the U.S. FDA has granted fast track designation for its lead compound ALM-488.
ALM-488 is an investigational fluorescently labelled nerve targeting pharmaceutical being developed as an adjunct for the visualisation of nerves at risk for injury during head and neck surgery.
